Cargando…

Structural Basis of Metallo-β-lactamase Inhibition by N-Sulfamoylpyrrole-2-carboxylates

[Image: see text] Metallo-β-lactamases (MBLs) can efficiently catalyze the hydrolysis of all classes of β-lactam antibiotics except monobactams. While serine-β-lactamase (SBL) inhibitors (e.g., clavulanic acid, avibactam) are established for clinical use, no such MBL inhibitors are available. We rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Farley, Alistair J. M., Ermolovich, Yuri, Calvopiña, Karina, Rabe, Patrick, Panduwawala, Tharindi, Brem, Jürgen, Björkling, Fredrik, Schofield, Christopher J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205225/
https://www.ncbi.nlm.nih.gov/pubmed/34003651
http://dx.doi.org/10.1021/acsinfecdis.1c00104
_version_ 1783708468524351488
author Farley, Alistair J. M.
Ermolovich, Yuri
Calvopiña, Karina
Rabe, Patrick
Panduwawala, Tharindi
Brem, Jürgen
Björkling, Fredrik
Schofield, Christopher J.
author_facet Farley, Alistair J. M.
Ermolovich, Yuri
Calvopiña, Karina
Rabe, Patrick
Panduwawala, Tharindi
Brem, Jürgen
Björkling, Fredrik
Schofield, Christopher J.
author_sort Farley, Alistair J. M.
collection PubMed
description [Image: see text] Metallo-β-lactamases (MBLs) can efficiently catalyze the hydrolysis of all classes of β-lactam antibiotics except monobactams. While serine-β-lactamase (SBL) inhibitors (e.g., clavulanic acid, avibactam) are established for clinical use, no such MBL inhibitors are available. We report on the synthesis and mechanism of inhibition of N-sulfamoylpyrrole-2-carboxylates (NSPCs) which are potent inhibitors of clinically relevant B1 subclass MBLs, including NDM-1. Crystallography reveals that the N-sulfamoyl NH(2) group displaces the dizinc bridging hydroxide/water of the B1 MBLs. Comparison of crystal structures of an NSPC and taniborbactam (VRNX-5133), presently in Phase III clinical trials, shows similar binding modes for the NSPC and the cyclic boronate ring systems. The presence of an NSPC restores meropenem efficacy in clinically derived E. coli and K. pneumoniae blaNDM-1. The results support the potential of NSPCs and related compounds as efficient MBL inhibitors, though further optimization is required for their clinical development.
format Online
Article
Text
id pubmed-8205225
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-82052252021-06-16 Structural Basis of Metallo-β-lactamase Inhibition by N-Sulfamoylpyrrole-2-carboxylates Farley, Alistair J. M. Ermolovich, Yuri Calvopiña, Karina Rabe, Patrick Panduwawala, Tharindi Brem, Jürgen Björkling, Fredrik Schofield, Christopher J. ACS Infect Dis [Image: see text] Metallo-β-lactamases (MBLs) can efficiently catalyze the hydrolysis of all classes of β-lactam antibiotics except monobactams. While serine-β-lactamase (SBL) inhibitors (e.g., clavulanic acid, avibactam) are established for clinical use, no such MBL inhibitors are available. We report on the synthesis and mechanism of inhibition of N-sulfamoylpyrrole-2-carboxylates (NSPCs) which are potent inhibitors of clinically relevant B1 subclass MBLs, including NDM-1. Crystallography reveals that the N-sulfamoyl NH(2) group displaces the dizinc bridging hydroxide/water of the B1 MBLs. Comparison of crystal structures of an NSPC and taniborbactam (VRNX-5133), presently in Phase III clinical trials, shows similar binding modes for the NSPC and the cyclic boronate ring systems. The presence of an NSPC restores meropenem efficacy in clinically derived E. coli and K. pneumoniae blaNDM-1. The results support the potential of NSPCs and related compounds as efficient MBL inhibitors, though further optimization is required for their clinical development. American Chemical Society 2021-05-18 2021-06-11 /pmc/articles/PMC8205225/ /pubmed/34003651 http://dx.doi.org/10.1021/acsinfecdis.1c00104 Text en © 2021 The Authors. Published by American Chemical Society Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Farley, Alistair J. M.
Ermolovich, Yuri
Calvopiña, Karina
Rabe, Patrick
Panduwawala, Tharindi
Brem, Jürgen
Björkling, Fredrik
Schofield, Christopher J.
Structural Basis of Metallo-β-lactamase Inhibition by N-Sulfamoylpyrrole-2-carboxylates
title Structural Basis of Metallo-β-lactamase Inhibition by N-Sulfamoylpyrrole-2-carboxylates
title_full Structural Basis of Metallo-β-lactamase Inhibition by N-Sulfamoylpyrrole-2-carboxylates
title_fullStr Structural Basis of Metallo-β-lactamase Inhibition by N-Sulfamoylpyrrole-2-carboxylates
title_full_unstemmed Structural Basis of Metallo-β-lactamase Inhibition by N-Sulfamoylpyrrole-2-carboxylates
title_short Structural Basis of Metallo-β-lactamase Inhibition by N-Sulfamoylpyrrole-2-carboxylates
title_sort structural basis of metallo-β-lactamase inhibition by n-sulfamoylpyrrole-2-carboxylates
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205225/
https://www.ncbi.nlm.nih.gov/pubmed/34003651
http://dx.doi.org/10.1021/acsinfecdis.1c00104
work_keys_str_mv AT farleyalistairjm structuralbasisofmetalloblactamaseinhibitionbynsulfamoylpyrrole2carboxylates
AT ermolovichyuri structuralbasisofmetalloblactamaseinhibitionbynsulfamoylpyrrole2carboxylates
AT calvopinakarina structuralbasisofmetalloblactamaseinhibitionbynsulfamoylpyrrole2carboxylates
AT rabepatrick structuralbasisofmetalloblactamaseinhibitionbynsulfamoylpyrrole2carboxylates
AT panduwawalatharindi structuralbasisofmetalloblactamaseinhibitionbynsulfamoylpyrrole2carboxylates
AT bremjurgen structuralbasisofmetalloblactamaseinhibitionbynsulfamoylpyrrole2carboxylates
AT bjorklingfredrik structuralbasisofmetalloblactamaseinhibitionbynsulfamoylpyrrole2carboxylates
AT schofieldchristopherj structuralbasisofmetalloblactamaseinhibitionbynsulfamoylpyrrole2carboxylates